Assuming an increase in median OS of @ months with RE versus sorafenib therapy , randomising at least @ patients ( @ in each treatment arm ) will be sufficient for @ % power and a bilateral alpha risk of @ % ; therefore , @ patients will be enrolled to allow for @ % loss of patients due to ineligibility .